iSpecimen Inc. (ISPC)
USD 1.27
(4.1%)
USD 1.27
(4.1%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 9.92 Million USD | -4.56% |
| 2022 | 10.4 Million USD | -6.58% |
| 2021 | 11.13 Million USD | 36.06% |
| 2020 | 8.18 Million USD | 90.4% |
| 2019 | 4.29 Million USD | -2.2% |
| 2018 | 4.39 Million USD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 2.86 Million USD | 25.05% |
| 2024 Q1 | 2.28 Million USD | -11.07% |
| 2023 Q4 | 2.57 Million USD | -7.3% |
| 2023 FY | 9.92 Million USD | -4.56% |
| 2023 Q3 | 2.77 Million USD | 70.92% |
| 2023 Q2 | 1.62 Million USD | -44.91% |
| 2023 Q1 | 2.95 Million USD | -0.38% |
| 2022 Q2 | 2.33 Million USD | -7.15% |
| 2022 Q1 | 2.51 Million USD | -1.19% |
| 2022 Q3 | 2.58 Million USD | 10.46% |
| 2022 FY | 10.4 Million USD | -6.58% |
| 2022 Q4 | 2.96 Million USD | 14.64% |
| 2021 Q2 | 2.9 Million USD | -2.02% |
| 2021 FY | 11.13 Million USD | 36.06% |
| 2021 Q1 | 2.96 Million USD | 9.05% |
| 2021 Q4 | 2.54 Million USD | -6.23% |
| 2021 Q3 | 2.71 Million USD | -6.38% |
| 2020 Q4 | 2.71 Million USD | 20.78% |
| 2020 FY | 8.18 Million USD | 90.4% |
| 2020 Q3 | 2.25 Million USD | 49.55% |
| 2020 Q2 | 1.5 Million USD | -12.1% |
| 2020 Q1 | 1.71 Million USD | 32.64% |
| 2019 FY | 4.29 Million USD | -2.2% |
| 2019 Q3 | 692.7 Thousand USD | 0.0% |
| 2019 Q4 | 1.29 Million USD | 86.29% |
| 2018 FY | 4.39 Million USD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Aspira Women's Health Inc. | 9.15 Million USD | -8.457% |
| bioAffinity Technologies, Inc. | 2.53 Million USD | -292.031% |
| Intelligent Bio Solutions Inc. | 3.11 Million USD | -219.052% |
| Standard BioTools Inc. | 106.34 Million USD | 90.664% |
| Inotiv, Inc. | 572.42 Million USD | 98.266% |
| Prenetics Global Limited | 21.74 Million USD | 54.338% |
| Neuronetics, Inc. | 71.34 Million USD | 86.085% |
| Star Equity Holdings, Inc. | 45.78 Million USD | 78.316% |
| Castle Biosciences, Inc. | 219.78 Million USD | 95.483% |
| Psychemedics Corporation | 22.09 Million USD | 55.072% |
| RadNet, Inc. | 1.61 Billion USD | 99.386% |
| Exact Sciences Corporation | 2.49 Billion USD | 99.603% |
| IDEXX Laboratories, Inc. | 3.66 Billion USD | 99.729% |
| OpGen, Inc. | 3.41 Million USD | -190.44% |
| Exagen Inc. | 52.54 Million USD | 81.106% |
| Bionano Genomics, Inc. | 36.11 Million USD | 72.51% |
| CareDx, Inc | 280.32 Million USD | 96.458% |
| Check-Cap Ltd. | - USD | -Infinity% |
| Twist Bioscience Corporation | 312.97 Million USD | 96.828% |
| Guardant Health, Inc. | 563.94 Million USD | 98.24% |
| Biodesix, Inc. | 49.08 Million USD | 79.774% |
| BioNexus Gene Lab Corp. | 9.77 Million USD | -1.611% |
| Precipio, Inc. | 15.19 Million USD | 34.67% |
| Natera, Inc. | 1.08 Billion USD | 99.083% |
| Fulgent Genetics, Inc. | 289.21 Million USD | 96.567% |
| Sera Prognostics, Inc. | 306 Thousand USD | -3144.505% |
| 23andMe Holding Co. | 219.63 Million USD | 95.48% |
| OPKO Health, Inc. | 863.49 Million USD | 98.85% |
| Personalis, Inc. | 73.48 Million USD | 86.489% |
| Aclaris Therapeutics, Inc. | 31.24 Million USD | 68.229% |
| Applied DNA Sciences, Inc. | 13.36 Million USD | 25.729% |
| T2 Biosystems, Inc. | 7.19 Million USD | -38.026% |
| Neogen Corporation | 924.22 Million USD | 98.926% |
| Myriad Genetics, Inc. | 678.4 Million USD | 98.537% |
| ICON Public Limited Company | 8.12 Billion USD | 99.878% |
| NeoGenomics, Inc. | 591.64 Million USD | 98.322% |
| Star Equity Holdings, Inc. | 45.78 Million USD | 78.316% |
| MDxHealth SA | 70.19 Million USD | 85.856% |
| Prenetics Global Limited | 21.74 Million USD | 54.338% |
| Illumina, Inc. | 4.5 Billion USD | 99.78% |
| DarioHealth Corp. | 20.35 Million USD | 51.218% |
| ENDRA Life Sciences Inc. | - USD | -Infinity% |
| Medpace Holdings, Inc. | 1.88 Billion USD | 99.474% |
| Mainz Biomed B.V. | 895.47 Thousand USD | -1008.701% |
| Trinity Biotech plc | 56.83 Million USD | 82.531% |
| Sotera Health Company | 1.04 Billion USD | 99.054% |
| bioAffinity Technologies, Inc. | 2.53 Million USD | -292.031% |